CIRM Funded Clinical Trials

In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major

Disease Area:
Alpha Thalassemia Major
CIRM Grant:
CLIN2-09183 (Active)
Award Value:
Trial Stage:
Phase 1
Trial Status:
Enrolling by invitation
Targeted Enrollment:
10 ID:


Dr. MacKenzie and her team at UCSF are using hematopoietic stem cells (HSCs) to treat babies in the womb who have alpha thalassemia major, a blood disorder that is almost always fatal. Current treatment requires in utero blood transfusions and monthly blood transfusions for life or a bone marrow transplant if a suitable donor is identified. In this trial, HSCs are taken from the mother’s bone marrow and transplanted into the baby before birth. The mother’s cells are able to survive and correct the defect in the baby’s blood cells, increasing the chances of a healthy birth and improving the chances of having effective treatments after birth.


Single arm, non-randomised study.


Safety and feasibility, efficacy.

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website